Recorded derivative valuation loss of 2,355 million yen as non-operating expenses for the second quarter of the fiscal year ending March 2027. Impacted by currency movements and widening Japan-U.S. interest rate differentials. No reflection in consolidated earnings guidance at this time. Any necessary future revisions will be promptly disclosed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Towa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4553-20261111-01.pdf","jir_short_summary":"Recorded derivative valuation loss of 2,355 million yen as non-operating expenses for the second quarter of the fiscal year ending March 2027. Impacted by currency movements and widening Japan-U.S. interest rate differentials. No reflection in consolidated earnings guidance at this time. Any necessary future revisions will be promptly disclosed.","jir_summary":"### Accounting Policy and Impact\nAccording to the interim financial summary disclosed today, a derivative valuation loss will be recorded as non-operating expenses in the second quarter of the fiscal year ending March 2027. The causes are a trend toward a stronger yen and a widening long-term interest rate differential between Japan and the United States. The company does not include derivative valuation gains or losses in its consolidated earnings guidance, and states that it will promptly disclose any future revisions if they occur.\n\n### Earnings Outlook and Future Response\nThe consolidated earnings guidance for the fiscal year ending March 2027 has not been specially revised since it was announced on May 14, 2026, and due to uncertainty in the foreign exchange market, derivative valuation gains and losses are not incorporated into the forecasts. If a revision becomes necessary in the future, the company will promptly notify stakeholders.","jir_financial_highlights":"Derivative valuation loss: 2,355 million yen (Unknown)","jir_category":"","jir_hashtags":"#TowaPharmaceutical, #Disclosure","jir_key_figures":"Derivative valuation loss: 2,355 million yen","jir_meta_title":"Towa Pharmaceutical Notice on Recording Derivative Valuation Loss\uff5cNovember 11, 2026","jir_meta_description":"Towa Pharmaceutical recorded a derivative valuation loss of 2,355 million yen as non-operating expenses in the second quarter of the fiscal year ending March 2027. The company discloses the potential impact on earnings guidance and its response policy.","jir_og_title":"Towa Pharmaceutical Announces Recording of Derivative Valuation Loss","jir_og_description":"Towa Pharmaceutical recorded a derivative valuation loss of 2,355 million yen in the interim period and discloses its outlook and response policy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-149181","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n